



University of Dundee

Reappraising the clinical impact of mepolizumab

Lipworth, Brian; Jabbal, Sunny

Published in:
Lancet

DOI:
[10.1016/S2213-2600\(17\)30183-2](https://doi.org/10.1016/S2213-2600(17)30183-2)

Publication date:
2017

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Lipworth, B. J., & Jabbal, S. (2017). Reappraising the clinical impact of mepolizumab. *Lancet*, 5(6), [e20]. DOI: [10.1016/S2213-2600\(17\)30183-2](https://doi.org/10.1016/S2213-2600(17)30183-2)

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Respiratory Medicine

Elsevier Editorial System(tm) for The Lancet

Manuscript Draft

Manuscript Number:

Title: Reappraising the clinical impact of mepolizumab

Article Type: Correspondence

Corresponding Author: Professor Brian Lipworth, MD

Corresponding Author's Institution: University of Dundee

First Author: Brian Lipworth, MD

Order of Authors: Brian Lipworth, MD; Sunny Jabbal, MBChB

Manuscript Region of Origin: UNITED KINGDOM

Reappraising the clinical impact of mepolizumab

BJ Lipworth MD, S Jabbal MBChB

Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, Scotland, DD1 9SY, UK

Correspondence: Dr BJ Lipworth, Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, Scotland, DD1 9SY, UK

Tel: +44 (0)1382 383188 b.j.lipworth@dundee.ac.uk

Word Count: 379

We read with interest the recent MUSCA trial from Chupp and colleagues¹ which concluded that mepolizumab was associated with significant improvements in health related quality of life (QOL) in patients with severe eosinophilic asthma (SEA) and therefore support its use as a favourable add-on treatment option to standard of care. Unfortunately there are several issues with the minimum clinically important difference (MCID) for the presented data which make this conclusion untenable.

The primary outcome of the St George's Respiratory Questionnaire (SGRQ) was specially designed for use in COPD rather than asthma², whereas the disease specific asthma quality of life questionnaire (AQLQ) is more appropriate to patients with asthma³. At end point after 24 weeks the mean change in SGRQ total score was -7.7 which although statistically significant only amounted to a "slightly effective" change (MCID >-4.0), but less than the MCID thresholds for a "moderately effective" change (>-8.0) or a "very effective" change (>-12)⁴. There appeared to be no difference in effects of mepolizumab on SGRQ according to low or high blood eosinophil counts, in turn suggesting that they chose the wrong QOL instrument for patients with SEA.

Moreover the 120 ml mean improvement in FEV1 was less than the MCID of 230ml⁵, while the mean change in asthma control questionnaire (ACQ) of -0.4 was also less than the MCID of -0.5³. For comparison in a study with dupilumab after 12 weeks there were mean improvements in ACQ (-0.73) and FEV1 (0.27) which both exceeded their respective MCID's⁶.

These findings all point to a statistically significant but clinically meaningless impact on quality of life, lung function and asthma control. Prescribers therefore need to be aware when following SEA patients with mepolizumab that its effects in reducing exacerbations may be disconnected from these other important clinical outcomes.

It is also worth noting that the MUSCA trial excluded patients who smoked, which means the findings may not be pertinent to more deprived areas where smoking is highly prevalent among asthma patients. Finally their cohort exhibited a mean reversibility to salbutamol of 21%, which in our experience is unusually high for patients with severe asthma. Hence we would have reservations that these findings from a highly selective group may not be generalizable to patients with SEA in a more real life setting.

References

1. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med* 2017.
2. Jones PW. St. George's Respiratory Questionnaire: MCID. *Copd* 2005; **2**(1): 75-9.
3. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med* 2005; **99**(5): 553-8.
4. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. *Eur Respir J* 2002; **19**(3): 398-404.
5. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? *Eur Respir J* 1999; **14**(1): 23-7.
6. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 2013; **368**(26): 2455-66.